The analysts wrote, ?Cornerstone Therapeutics (CRTX) has been upgraded by TheStreet Ratings from sell to hold. The company?s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company?s earnings per share.? Shares of Cornerstone Therapeutics traded down 1.00% during mid-day trading on Monday, hitting $6.92. Cornerstone Therapeutics has a 52 week low of $3.10 and a 52 week high of $7.99. The stock?s 50-day moving average is currently $5.95. The company?s market cap is $182.0 million. Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets. To view TheStreet?s full report, visit www.thestreetratings.com